The new solution, Investigational Product RIMS, will provide key foundational RIMS functionality to organizations poised for future growth.
Miami, Florida, February 2, 2023– ArisGlobal, the leading provider of life sciences software designed to automate core drug development functions with its end-to-end technology platform LifeSphere®, today announces the launch of Investigational Product RIMS, an offering purpose built to meet the unique needs of life sciences and medical device companies as they progress through the investigational stages of drug development.
A pre-validated, turnkey solution, Investigational Product RIMS is ideal for emerging life sciences and medical device companies that have yet to receive marketing authorization for their products. To that end, cost and complexity are reduced by focusing on functionality that’s a high priority such as investigational submission and dossier planning, clinical trial authorization tracking and health authority commitment management.
“Companies working toward marketing authorization cannot afford for technology to be a burden and increase organizational complexity,” said Jim Hilferty, Associate Vice President of Regulatory Products at ArisGlobal. “Investigational Product RIMS is designed to focus on the functionality needed to achieve the next clinical or regulatory milestone. As an added benefit, companies working in a compliant system built for life sciences can present a more polished, investor-ready package of product assets to support growth.”
“As companies needs evolve, Investigational Product RIMS makes it possible to step into more advanced functionality with little organizational disruption,” adds Hilferty. “You can repurpose accepted investigational submission content to apply for marketing authorization once regulators give the green light and turn on features like global registration tracking as a product portfolio matures.”
Key Features of LifeSphere Investigational Product
- Investigational submission and dossier planning with intelligent automation and activity triggers to drive efficiency
- Clinical trial authorization tracking to meet regulatory deadlines and expedite time to market
- Health authority commitment management for end-to-end planning and tracking of interactions, commitments, and obligations
To learn more about LifeSphere Investigational Product, join ArisGlobal Regulatory product leaders for the March 7 webinar, ‘Right Sized’ RIMS: Discover a purpose-built solution for investigational-stage companies.
LifeSphere Regulatory was introduced as an end-to-end platform in 2019 and has since received several industry accolades, including being lauded as the “Market Leader in IDMP Readiness” in Gens & Associates’ 2021 IDMP Software Vendor Readiness and Capability report.
—–###—–
About LifeSphere: LifeSphere® is the trusted partner for global pharmaceutical and biotechnology companies, health authorities, and contract research organizations. Helping accelerate product development, organize clinical trials, manage compliance, and streamline collaboration across teams, LifeSphere empowers safer, faster life science breakthroughs. As the flagship platform of ArisGlobal, LifeSphere is a market-leading solution built on 35 years of industry partnership and continues to evolve in collaboration with hundreds of trusted customers worldwide. For more information visit lifesphere.arisglobal.com.
About ArisGlobal: ArisGlobal is led by passionate individuals who support life sciences leaders in developing and monitoring breakthrough medicines and therapies. With more than 35 years of expertise in the life sciences industry, ArisGlobal develops technology products within the platform LifeSphere to power pharmaceutical and biotech research and development. Building on our commitment to corporate social responsibility and sustainability initiatives, we give back to the communities where we live and work – in the U.S, Europe, India, Japan, and China. For more information visit https://www.arisglobal.com/https://www.arisglobal.com/
